Treprostinil (Remodulin)

Remodulin (treprostinil) is covered for FDA‑approved pulmonary arterial hypertension (WHO Group I) — including transition from epoprostenol — and for compendial off‑label use in CTEPH, and is not covered for uses outside these indications. Key requirements include right‑heart catheterization confirmation of PAH, NYHA class III–IV (or class II with prior oral or inhaled/parenteral prostacyclin therapy), prescriber pulmonologist/cardiologist involvement, vasodilator testing and CCB trial rules for idiopathic PAH, continuous subcutaneous or IV infusion only, initial/renewal approvals limited to 6 months with documented clinical benefit for reauthorization, and a 30‑day short supply if criteria or information are lacking.

"For idiopathic PAH: the individual "has had acute vasodilator test done during the right heart catheterization unless he/she was unable to undergo a vasodilator test" and either "Had an acute respo..."